Erratum: PRISMA harms checklist: Improving harms reporting in systematic reviews ((BMJ Online (2016) 352 (i157) DOI: 10.1136/bmj.i157);PRISMA harms checklist: Improving harms reporting in systematic reviews

The BMJ

Volumn 352, Issue , 2016, Pages

  Zorzela, Liliane ^a   Loke, Yoon K ^b   Ioannidis, John P ^c   Golder, Su ^d   Santaguida, Pasqualina ^e   Altman, Douglas G ^f   Moher, David ^g   Vohra, Sunita ^a   Boon, Heather ^h   Clark, Jocalyn ^h   Derry, Sheena ⁱ   Gallivan, Jim ^j   Gardiner, Paula ^k   Gøtzsche, Peter ^l   Loder, Elizabeth ^t   Napoli, Maryann ^m   Pilkington, Karen ⁿ   Shekelle, Paul ^o   Singh, Sonal ^p   Witt, Claudia ^q   Lasserson, Toby ^r   Wu, Taixiang ^s   Shamseer, Larissa ^g   Mulrow, Cynthia ^t   more..

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF YORK   (United Kingdom)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j HEALTH CANADA   (Canada)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Nordic Cochrane Center   (United Kingdom)

^m Center for Medical Consumers   (United Kingdom)

ⁿ UNIVERSITY OF WESTMINSTER   (United Kingdom)

^o VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^p JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF ZURICH   (Switzerland)

^r Cochrane Editorial Unit ^*  (United Kingdom)

^s Chinese Cochrane Center   (China)

^t University of Ottawa ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; CHECKLIST; DANGER, RISK, SAFETY AND RELATED PHENOMENA; HARM; HUMAN; MEDICAL DOCUMENTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SAFETY; SELF REPORT; DELPHI STUDY; EVIDENCE BASED MEDICINE; LITERATURE; METHODOLOGY; PUBLISHING; STANDARDS;

CHECKLIST; DELPHI TECHNIQUE; EVIDENCE-BASED MEDICINE; HUMANS; PUBLISHING; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC;

EID: 84959259456     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i2229     Document Type: Erratum

References (85)

1. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. doi:10.1371/journal.pmed.1000097.
2. Gray JAM. Evidence-based healthcare. How to make health policy and management decisions.Churchill Livingstone, 2001.
3. Sackett DL, Wennberg JE. Choosing the best research design for each question. BMJ 1997;315:1636. doi:10.1136/bmj.315.7123.1636.
4. Ioannidis JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 2009;169:1737-9. doi:10.1001/archinternmed.2009.313.
5. Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials 2012;13:138. doi:10.1186/1745-6215-13-138.
6. Papanikolaou PN, Ioannidis JP. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. Am J Med 2004;117:582-9. doi:10.1016/j.amjmed.2004.04.026.
7. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009;169:1756-61. doi:10.1001/archinternmed.2009.306.
8. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clin Pharmacol 2001;1:3. doi:10.1186/1472-6904-1-3.
9. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285:437-43. doi:10.1001/jama.285.4.437.
10. Yazici Y. Some concerns about adverse event reporting in randomized clinical trials. Bull NYU Hosp Jt Dis 2008;66:143-5.
11. Ernst E, Pittler MH. Assessment of therapeutic safety in systematic reviews: literature review. BMJ 2001;323:546. doi:10.1136/bmj.323.7312.546.
12. Zorzela L, Golder S, Liu Y, et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ 2014;348:f7668. doi:10.1136/bmj.f7668.
13. Golder S, Loke YK, Zorzela L. Some improvements are apparent in identifying adverse effects in systematic reviews from 1994 to 2011. J Clin Epidemiol 2013;66:253-60. doi:10.1016/j.jclinepi.2012.09.013.
14. McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic reviews. BMC Med Res Methodol 2004;4:19. doi:10.1186/1471-2288-4-19.
15. Cornelius VR, Perrio MJ, Shakir SA, Smith LA. Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality. Pharmacoepidemiol Drug Saf 2009;18:1223-31. doi:10.1002/pds.1844.
16. Loke YK, Golder SP, Vandenbroucke JP. Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources. Ther Adv Drug Saf 2011;2:59-68. doi:10.1177/2042098611401129.
17. Chou R, Fu R, Carson S, Saha S, Helfand M. Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions. J Clin Epidemiol 2007;60:18-28. doi:10.1016/j.jclinepi.2006.02.021.
18. Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med 2005;142:1090-9. doi:10.7326/0003-4819-142-12-Part-2-200506211-00009.
19. Hopewell S, Wolfenden L, Clarke M. Reporting of adverse events in systematic reviews can be improved: survey results. J Clin Epidemiol 2008;61:597-602. doi:10.1016/j.jclinepi.2007.10.005.
20. Hernandez AV, Walker E, Ioannidis JP, Kattan MW. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. Am Heart J 2008;156:23-30. doi:10.1016/j.ahj.2008.03.002.
21. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12. doi:10.1001/jama.283.15.2008.
22. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med 2010;7:e1000217. doi:10.1371/journal.pmed.1000217.
23. Beller EM, Glasziou PP, Altman DG, et al. PRISMA for Abstracts Group. PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med 2013;10:e1001419. doi:10.1371/journal.pmed.1001419.
24. Shamseer L, Moher D, Clarke M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647. doi:10.1136/bmj.g7647.
25. Pilkington K, Boshnakova A. Complementary medicine and safety: a systematic investigation of design and reporting of systematic reviews. Complement Ther Med 2012;20:73-82. doi:10.1016/j.ctim.2011.10.002.
26. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998;2:i-iv, 1-88.
27. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. Cochrane Collaboration, 2011. www.cochrane-handbook.org.
28. Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol 2010;63:502-12. doi:10.1016/j.jclinepi.2008.06.007.
29. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-8. doi:10.7326/0003-4819-141-10-200411160-00009.
30. Loke YK, Price D, Herxheimer A. Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007;7:32. doi:10.1186/1471-2288-7-32.
31. Arbyn M, Kyrgiou M, Simoens C, et al Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.
32. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009;32:219-28. doi:10.2165/00002018-200932030-00004.
33. Hartley J. Clarifying the abstracts of systematic literature reviews. Bull Med Libr Assoc 2000;88:332-7.
34. Banach R, Boskovic R, Einarson T, Koren G. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf 2010;33:73-9. doi:10.2165/11317640-000000000-00000.
35. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011;342:d1309. doi:10.1136/bmj.d1309.
36. Agbabiaka TB, Pittler MH, Wider B, Ernst E. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf 2009;32:637-47. doi:10.2165/00002018-200932080-00003.
37. Hammad TA, Neyarapally GA, Pinheiro SP, Iyasu S, Rochester G, Dal Pan G. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment. Clin Trials 2013;10:389-97. doi:10.1177/1740774513479467.
38. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium - the FDA's conclusions. N Engl J Med 2010;363:1097-9. doi:10.1056/NEJMp1008502.
39. Anello C, O'Neill RT. Does research synthesis have a place in drug regulatory policy? Clin Res Regul Aff 1996;13:13-21doi:10.3109/10601339609019625. .
40. Golder S, Loke Y, McIntosh HM. Room for improvement? A survey of the methods used in systematic reviews of adverse effects. BMC Med Res Methodol 2006;6:3. doi:10.1186/1471-2288-6-3.
41. Golder S, Loke YK, Bland M. Unpublished data can be of value in systematic reviews of adverse effects: methodological overview. J Clin Epidemiol 2010;63:1071-81. doi:10.1016/j.jclinepi.2010.02.009.
42. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011;342:d2234. doi:10.1136/bmj.d2234.
43. Golder S, Loke Y, McIntosh HM. Poor reporting and inadequate searches were apparent in systematic reviews of adverse effects. J Clin Epidemiol 2008;61:440-8. doi:10.1016/j.jclinepi.2007.06.005.
44. Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol 2001;1:7. doi:10.1186/1471-2288-1-7.
45. Golder S, Loke YK. The contribution of different information sources for adverse effects data. Int J Technol Assess Health Care 2012;28:133-7. doi:10.1017/S0266462312000128.
46. Golder S, Loke YK. Failure or success of electronic search strategies to identify adverse effects data. J Med Libr Assoc 2012;100:130-4. doi:10.3163/1536-5050.100.2.012.
47. Bellis JR, Pirmohamed M, Nunn AJ, et al. Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis. Br J Anaesth 2014;113:23-42. doi:10.1093/bja/aeu152.
48. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45. doi:10.1136/ard.2008.091025.
49. Albavera-Hernández C, Rodríguez JM, Idrovo AJ. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clin Rehabil 2009;23:394-407. doi:10.1177/0269215508099860.
50. Rücker G, Schwarzer G, Carpenter J, Olkin I. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med 2009;28:721-38. doi:10.1002/sim.3511.
51. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77. doi:10.1002/sim.2528.
52. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data[correction in: Stat Med 2006; 25:2700]. Stat Med 2004;23:1351-75. doi:10.1002/sim.1761.
53. Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med 2010;29:3046-67. doi:10.1002/sim.4040.
54. Mattishent K, Loke YK. Bi-directional Interaction Between Hypoglycaemia And Cognitive Impairment In Elderly Patients Treated with Glucose Lowering Agents: Systematic Review and Meta-analysis. Diabetes Obes Metab 2015.
55. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ 2014;349:g6501. doi:10.1136/bmj.g6501.
56. Loke YK, Mattishent K. If nothing happens, is everything all right? Distinguishing genuine reassurance from a false sense of security. CMAJ 2015;187:15-6. doi:10.1503/cmaj.141344.
57. Kirkham JJ, Dwan KM, Altman DG, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. doi:10.1136/bmj.c365.
58. Page MJ, McKenzie JE, Kirkham J, et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. Cochrane Database Syst Rev 2014;10:MR000035. doi:10.1002/14651858.MR000035.pub2.
59. Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. Am J Gastroenterol 2009;104:546-51. doi:10.1038/ajg.2008.22.
60. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65. doi:10.1001/jama.291.20.2457.
61. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 2006;24:3933-8. doi:10.1200/JCO.2005.05.3959.
62. Mahoney MR, Sargent DJ. Adverse-event rates: journals versus databases. Lancet 2007;369:171-2. doi:10.1016/S0140-6736(07)60086-5.
63. Chan AW, Krleza-Jeriæ K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004;171:735-40. doi:10.1503/cmaj.1041086.
64. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002. doi:10.1136/bmj.d4002.
65. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600. doi:10.1136/bmj.333.7568.597.
66. Lathyris D, Panagiotou OA, Baltogianni M, Ioannidis JP, Contopoulos-Ioannidis DG. Safety of medical interventions in children versus adults. Pediatrics 2014;133:e666-73. doi:10.1542/peds.2013-3128.
67. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215. doi:10.1136/bmj.d3215.
68. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ 2008;336:1413-5. doi:10.1136/bmj.a117.
69. Bain ES, Middleton PF, Crowther CA. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy Childbirth 2013;13:195. doi:10.1186/1471-2393-13-195.
70. Langendam MW, Tiemersma EW, van der Werf MJ, Sandgren A. Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review. PLoS One 2013;8:e53599. doi:10.1371/journal.pone.0053599.
71. Jolivot PA, Hindlet P, Pichereau C, et al. A systematic review of adult admissions to ICUs related to adverse drug events. Crit Care 2014;18:643. doi:10.1186/s13054-014-0643-5.
72. Kötter T, da Costa BR, Fässler M, et al. Metamizole-associated adverse events: a systematic review and meta-analysis. PLoS One 2015;10:e0122918. doi:10.1371/journal.pone.0122918.
73. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?J Hosp Med 2010;5:E8-16. doi:10.1002/jhm.691.
74. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med 1965;58:295-300.
75. Uppsala Monitoring Centre. World Health Organization causality assessment criteria. 2015. who-umc.org.
76. Shuster JJ, Jones LS, Salmon DA. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Stat Med 2007;26:4375-85. doi:10.1002/sim.3060.
77. Shuster JJ. Empirical vs natural weighting in random effects meta-analysis. Stat Med 2010;29:1259-65. doi:10.1002/sim.3607.
78. Ioannidis JP, Hozo I, Djulbegovic B. Optimal type I and type II error pairs when the available sample size is fixed. J Clin Epidemiol 2013;66:903-910.e2. doi:10.1016/j.jclinepi.2013.03.002.
79. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75. doi:10.1210/jc.2009-2575.
80. Hohl CM, Kelly-Smith CH, Yeung TC, Sweet DD, Doyle-Waters MM, Schulzer M. The effect of a bolus dose of etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med 2010;56:105-13.e5. doi:10.1016/j.annemergmed.2010.01.030.
81. Moher D, Glasziou P, Chalmers I, et al. Increasing value and reducing waste in biomedical research: who's listening? Lancet 2015,. doi:10.1016/S0140-6736(15)00307-4.
82. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet 2014;383:267-76. doi:10.1016/S0140-6736(13)62228-X. 24411647.
83. Shamseer L, Galipeau J, Turner L, Moher D. Improving the reporting and usability of research studies. Can J Anaesth 2013;60:337-44. doi:10.1007/s12630-013-9895-9.
84. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev 2012;1:60. doi:10.1186/2046-4053-1-60.
85. Macleod MR, Michie S, Roberts I, et al. Biomedical research: increasing value, reducing waste. Lancet 2014;383:101-4. doi:10.1016/S0140-6736(13)62329-6.